[go: up one dir, main page]

UY28693A1 - USEFUL COMPOUNDS IN THERAPY - Google Patents

USEFUL COMPOUNDS IN THERAPY

Info

Publication number
UY28693A1
UY28693A1 UY28693A UY28693A UY28693A1 UY 28693 A1 UY28693 A1 UY 28693A1 UY 28693 A UY28693 A UY 28693A UY 28693 A UY28693 A UY 28693A UY 28693 A1 UY28693 A1 UY 28693A1
Authority
UY
Uruguay
Prior art keywords
therapy
useful compounds
useful
memeoria
het6
Prior art date
Application number
UY28693A
Other languages
Spanish (es)
Inventor
Justin Stephen Bryans
Thomas Ryckmans
Lee Richard Roberts
Patrick Stephen Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329693A external-priority patent/GB0329693D0/en
Priority claimed from GB0408789A external-priority patent/GB0408789D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY28693A1 publication Critical patent/UY28693A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Un compuesto de fórmula (I) o derivados del mismo aceptables farmacéuticamente, en el que:x,a,b,R, Het, c, d, R1, Het1, V, A, Q, R2, Z, R3, e, f, Het2, Het3, R4, R5, Het4, Het5 y Het6; son como fueron definidos en la memeoria y reivindicaciones y que son útiles para tratar en trastorno para el cual esta indicado un antagonista de V1a, en particular la dismenorrea.A compound of formula (I) or pharmaceutically acceptable derivatives thereof, wherein: x, a, b, R, Het, c, d, R1, Het1, V, A, Q, R2, Z, R3, e, f, Het2, Het3, R4, R5, Het4, Het5 and Het6; they are as defined in the memeoria and claims and which are useful for treating in a disorder for which a V1a antagonist is indicated, in particular dysmenorrhea.

UY28693A 2003-12-22 2004-12-21 USEFUL COMPOUNDS IN THERAPY UY28693A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0329693A GB0329693D0 (en) 2003-12-22 2003-12-22 Compounds useful in therapy
GB0408789A GB0408789D0 (en) 2004-04-20 2004-04-20 Triazole derivatives

Publications (1)

Publication Number Publication Date
UY28693A1 true UY28693A1 (en) 2005-07-29

Family

ID=34740750

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28693A UY28693A1 (en) 2003-12-22 2004-12-21 USEFUL COMPOUNDS IN THERAPY

Country Status (24)

Country Link
EP (1) EP1701959A1 (en)
JP (1) JP4698604B2 (en)
KR (1) KR100854872B1 (en)
AP (1) AP2331A (en)
AR (1) AR047340A1 (en)
AU (1) AU2004309164B2 (en)
BR (1) BRPI0417267A (en)
CA (1) CA2551038C (en)
CR (1) CR8481A (en)
DO (1) DOP2004001062A (en)
EA (1) EA010132B1 (en)
EC (1) ECSP066647A (en)
GE (1) GEP20084571B (en)
IL (1) IL176349A (en)
IS (1) IS8472A (en)
MA (1) MA28393B1 (en)
NL (1) NL1027833C2 (en)
NO (1) NO20063380L (en)
OA (1) OA13347A (en)
PA (1) PA8620501A1 (en)
PE (1) PE20051051A1 (en)
TW (1) TWI287541B (en)
UY (1) UY28693A1 (en)
WO (1) WO2005063754A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
MX2007003325A (en) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AR051090A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
JP5149009B2 (en) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド Pyridazine derivatives for inhibiting human stearoyl-CoA desaturase
AR051093A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
MX2007003332A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
KR20070083781A (en) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous of Cinnamid Compound
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2616937A1 (en) * 2005-07-29 2007-02-08 F. Hoffman-La Roche Ag Indol-3-yl-carbonyl-piperidin and piperazin derivatives
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
AR062095A1 (en) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd CINAMIDE COMPOUND PROFARMACO
RU2009119393A (en) * 2006-12-07 2011-01-20 Ф. Хоффманн-Ля Рош Аг (Ch) SPIROPIPERIDINE DERIVATIVES
EP2102207B1 (en) * 2006-12-07 2010-06-02 F.Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
JP2010513385A (en) * 2006-12-22 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー Spiro-piperidine derivatives
ES2351949T3 (en) * 2006-12-29 2011-02-14 F. Hoffmann-La Roche Ag DERIVATIVES OF AZASPIRO.
PE20081791A1 (en) 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd TWO CYCLIC DERIVATIVES OF OXOMORPHOLIN
CN101815713B (en) 2007-08-31 2013-09-11 卫材R&D管理有限公司 Polycyclic compounds
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US8470819B2 (en) 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
AU2011308403B2 (en) 2010-10-01 2014-08-21 Taisho Pharmaceutical Co., Ltd. 1,2,4-triazolone derivative
JP6506248B2 (en) 2013-03-14 2019-04-24 ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー Bicyclic analgesic compound
KR102380609B1 (en) 2013-12-12 2022-03-30 리커리엄 아이피 홀딩스, 엘엘씨 Bicyclic alkyl compounds and synthesis
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
KR20170048588A (en) 2014-09-17 2017-05-08 카리라 파마슈티컬스, 아이앤씨. Bicyclic compounds
ES2712886T3 (en) 2014-09-24 2019-05-16 Bayer Pharma AG Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa
SG11201703199UA (en) 2014-11-03 2017-05-30 Bayer Pharma AG Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
RU2637101C2 (en) * 2016-01-11 2017-11-29 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) Device for determination of aspired dose of aerosols
WO2017144624A1 (en) * 2016-02-23 2017-08-31 Servicio Andaluz De Salud Piperazine derivatives as antiviral agents with increased therapeutic activity
US10526314B2 (en) 2016-05-03 2020-01-07 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
AR108265A1 (en) 2016-05-03 2018-08-01 Bayer Pharma AG FENILTRIAZOL DERIVATIVES REPLACED WITH AMIDA AND USES OF THESE
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
EP3452457B1 (en) 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
EP3456716A4 (en) * 2016-05-09 2019-11-06 Nippon Soda Co., Ltd. CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT
US10927098B2 (en) 2016-10-20 2021-02-23 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
MX389668B (en) 2017-05-15 2025-03-20 Recurium Ip Holdings Llc Analgesic compounds
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
SG11202003049WA (en) 2017-10-24 2020-04-29 Bayer Ag Prodrugs of substituted triazole derivatives and uses thereof
US11230540B2 (en) 2017-10-24 2022-01-25 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Prodrugs of substituted triazole derivatives and uses thereof
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
HUE071972T2 (en) 2020-01-29 2025-10-28 Kamari Pharma Ltd Compounds and compositions for use in treating skin disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481360A (en) * 1983-08-26 1984-11-06 The Upjohn Company 4H-1,2,4-Triazol-3-yl compounds
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
PL359340A1 (en) * 2000-05-19 2004-08-23 Triazole derivatives

Also Published As

Publication number Publication date
EA010132B1 (en) 2008-06-30
PA8620501A1 (en) 2005-08-04
IL176349A (en) 2011-11-30
EA200600925A1 (en) 2006-12-29
EP1701959A1 (en) 2006-09-20
MA28393B1 (en) 2007-01-02
WO2005063754A1 (en) 2005-07-14
TW200528099A (en) 2005-09-01
AP2331A (en) 2011-12-05
KR20060101546A (en) 2006-09-25
CA2551038A1 (en) 2005-07-14
CA2551038C (en) 2010-04-27
GEP20084571B (en) 2008-12-25
ECSP066647A (en) 2006-10-25
PE20051051A1 (en) 2005-12-17
BRPI0417267A (en) 2007-04-17
HK1095822A1 (en) 2007-07-06
AU2004309164B2 (en) 2007-11-15
IL176349A0 (en) 2006-10-05
CR8481A (en) 2007-12-04
JP2007515468A (en) 2007-06-14
DOP2004001062A (en) 2005-06-30
OA13347A (en) 2007-04-13
JP4698604B2 (en) 2011-06-08
NL1027833C2 (en) 2006-03-06
AR047340A1 (en) 2006-01-18
AU2004309164A1 (en) 2005-07-14
KR100854872B1 (en) 2008-08-28
NL1027833A1 (en) 2005-06-23
AP2006003631A0 (en) 2006-06-30
IS8472A (en) 2006-05-18
TWI287541B (en) 2007-10-01
NO20063380L (en) 2006-09-22

Similar Documents

Publication Publication Date Title
UY28693A1 (en) USEFUL COMPOUNDS IN THERAPY
AR074435A1 (en) DERIVATIVES OF 1,3-BENZOTIAZOL, DRUGS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF CANCER.
PA8557401A1 (en) PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
TW200740818A (en) Cyclic anilino - pyridinotriazines
ATE479687T1 (en) KINASE INHIBITORS
CO5700767A2 (en) TRANSPLANT REJECTION TREATMENT PROCEDURE
CY1109764T1 (en) Substituted benzazoles and their use as RAF suspensions
ECSP088210A (en) SUBSTITUTED BENCIMIDAZOLS AND PREPARATION METHODS
CY1109322T1 (en) PROLINE PRODUCERS AND THEIR USE AS DIPLOMATIC PIPES
UY28201A1 (en) USEFUL TRIAZOL COMPOUNDS IN THERAPY
DE60328010D1 (en) HETEROCYCLIC COMPOUNDS
ATE460159T1 (en) USE OF 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYLAMINES, 3-BENZYL-3 HYDROXY-2-AMINO-PROPIONIC ACID AMIDE AND RELATED COMPOUNDS AS ANALGESICS
EA200801428A1 (en) PYRIDIAZINONE DERIVATIVES FOR THE TREATMENT OF TUMORS
CL2008003854A1 (en) Compounds derived from 2-benzylpyridazinone, inhibitors, regulators and / or modulators of meth-kinase; pharmaceutical composition; preparation procedure; and use in the treatment of a solid tumor, blood or immune system; pharmaceutical kit comprising an amount of said compound.
CY1113911T1 (en) SF5 DERIVATIVES AS PAR1 INHIBITORS, THEIR PREPARATION AND THEIR USE AS MEDICINES
MX2022001161A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents.
TW200640926A (en) Pyrazolopyrimidines
CY1112555T1 (en) CHEMICAL COGNITION PROCESSING WITH A DEROYLIC ACID FINISH
DK2231590T3 (en) ANTI-TUMOR COMPOUNDS
UY30009A1 (en) BENZOILPIRAZOL AND HERBICIDE COMPOUNDS CONTAINING THEM
ATE543803T1 (en) 3-Ä2-(3-AZYLAMINO-2-OXO-2H-PYRIDINE-1-YL)ACETYLAMINOÜ-4-OXOPENTANIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS
BRPI0519267A2 (en) quinoline derivative, its use, production and medicine containing the same
ATE488510T1 (en) HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE
ATE403655T1 (en) IMIDAZOPYRIDINE DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS
SV2008002512A (en) AMINO ACID DERIVATIVES REF. PC32769A

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20140310